Bochner Bruce S
Division of Allergy and Clinical Immunology, The Johns Hopkins University School of Medicine, Baltimore, MD, USA.
J Allergy Clin Immunol. 2004 Jan;113(1):3-9; quiz 10. doi: 10.1016/j.jaci.2003.09.046.
Eosinophils are regarded by many as fundamental to the pathophysiology of allergic diseases, including asthma. An improved understanding of the mechanisms involved in these responses is therefore of great relevance to asthma pathogenesis and the development of new therapeutics. Most therapies that are effective in reducing allergic inflammation in animals and human subjects diminish tissue eosinophilia and levels of eosinophil-derived mediators. However, recent efforts with more selective eosinophil-suppressive therapies have failed to affect disease, bringing into question the role of eosinophils in asthma. This article will provide a brief overview of the role of eosinophils in allergic diseases, followed by a discussion of both eosinophil-specific and eosinophil-selective therapeutic targets, with a focus on cell-surface molecules. The known and theoretic benefits and risks of these strategies will also be covered.
许多人认为嗜酸性粒细胞是包括哮喘在内的过敏性疾病病理生理学的基础。因此，深入了解这些反应所涉及的机制对于哮喘的发病机制和新疗法的开发具有重要意义。大多数在动物和人类受试者中有效减轻过敏性炎症的疗法都会减少组织嗜酸性粒细胞和嗜酸性粒细胞衍生介质的水平。然而，最近采用更具选择性的嗜酸性粒细胞抑制疗法的努力未能影响疾病，这使得嗜酸性粒细胞在哮喘中的作用受到质疑。本文将简要概述嗜酸性粒细胞在过敏性疾病中的作用，随后讨论嗜酸性粒细胞特异性和嗜酸性粒细胞选择性治疗靶点，重点是细胞表面分子。还将涵盖这些策略已知的和理论上的益处与风险。
